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ABSTRACT Scrub typhus is a potentially lethal infection caused by the obligate
intracellular bacterium Orientia tsutsugamushi. Reports on the emergence of doxycycline-
resistant strains highlight the urgent need to develop novel antiinfectives against
scrub typhus. Corallopyronin A (CorA) is a novel -pyrone compound synthesized by
the myxobacterium Corallococcus coralloides that was characterized as a noncompet-
itive inhibitor of the switch region of the bacterial RNA polymerase (RNAP). We
investigated the antimicrobial action of CorA against the human-pathogenic Karp
strain of O. tsutsugamushi in vitro and in vivo. The MIC of CorA against O. tsutsuga-
mushi was remarkably low (0.0078 g/ml), 16-fold lower than that against Rickettsia
typhi. In the lethal intraperitoneal O. tsutsugamushi mouse infection model, a mini-
mum daily dose of 100 g CorA protected 100% of infected mice. Two days of
treatment were sufﬁcient to confer protection. In contrast to BALB/c mice, SCID mice
succumbed to the infection despite treatment with CorA or tetracycline, suggesting
that antimicrobial treatment required synergistic action of the adaptive immune re-
sponse. Similar to tetracycline, CorA did not prevent latent infection of O. tsutsuga-
mushi in vivo. However, latency was not caused by acquisition of antimicrobial resis-
tance, since O. tsutsugamushi reisolated from latently infected BALB/c mice remained
fully susceptible to CorA. No mutations were found in the CorA-binding
regions of the  and = RNAP subunit genes rpoB and rpoC. Inhibition of the RNAP
switch region of O. tsutsugamushi by CorA is therefore a novel and highly potent
target for antimicrobial therapy for scrub typhus.
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Scrub typhus, the disease caused by Orientia tsutsugamushi, is a potentially fatalmite-borne infection that is endemic in the Asia-Paciﬁc region. Worldwide, more
than 1 billion people are estimated to be at risk to acquire the infection (1). Recent
reports from other continents suggest that the global distribution of Orientia species
may have been largely underestimated (2–5). Despite its medical importance, only a
limited set of drug targets is available for therapeutic use. Treatment strategies cur-
rently encompass two approaches: i) bacterial ribosomal protein biosynthesis can be
inhibited by tetracyclines (e.g., doxycycline), macrolides (e.g., azithromycin), or chlor-
amphenicol, and ii) RNA transcription by the bacterial RNA polymerase (RNAP) can be
inhibited by rifamycins (e.g., rifampin). Although it has not been investigated if resis-
tance to rifampin occurs in O. tsutsugamushi, rifampin resistance can be experimentally
induced in typhus group rickettsiae (6, 7) and was found in naturally occurring strains
of spotted fever group rickettsiae (8), both close relatives of O. tsutsugamushi. More
importantly, reports on doxycycline-resistant scrub typhus in regions where it is highly
endemic emphasize the urgent need to identify novel therapeutic drug targets in O.
tsutsugamushi (9, 10).
In the development of novel antimicrobials, inhibition of bacterial RNAP is regarded
as a particularly promising approach. However, only two groups of RNAP inhibitors are
clinically available for the treatment of bacterial infections. Besides rifamycins, which
have an indispensable role in tuberculosis therapy (11), ﬁdaxomicin has been devel-
oped for clinical use and is nowadays used to treat Clostridium difﬁcile infections (12).
While rifampin is an established therapy in scrub typhus, the activity of ﬁdaxomicin
against O. tsutsugamushi is unknown. Recent work has revealed the RNAP switch region
as a novel antimicrobial drug target. RNA transcription requires opening and closing of
the RNAP = subunit clamp that swings on the base of the refolding switch region (13,
14). This movement can be blocked allosterically by compounds from the group of
-pyrone antibiotics (corallopyronin and myxopyronin) (13, 14), ripostatin (13), squara-
mides (15), and others.
It was the aim of the present study to investigate whether corallopyronin A (CorA),
a myxobacterial natural product for which the biosynthetic pathway is known (16) and
that binds in this switch region (13, 14), could be a potential antimicrobial agent against
O. tsutsugamushi. CorA was ﬁrst isolated from the myxobacterium Corallococcus coral-
loides in the 1980s (17, 18) and was shown to inhibit RNA transcription in Gram-positive
bacteria (18). Binding of CorA (and myxopyronin) causes refolding of the highly
conserved switch 2 segment, which results in a distorted, inactive promoter complex
(14). Consequently, CorA locks the RNAP clamp, preventing the entry of double-
stranded DNA templates into the enzyme (hinge jamming) (13). The CorA binding
determinant encompasses a signiﬁcant fraction of the RNAP switch region, including
switch 2 and adjacent segments of the  and = subunits (13, 19). Importantly, this
binding site is remote from the binding site of rifamycins (13), which prevents the
development of cross-resistance.
Low bacterial membrane permeability for antimicrobial compounds (20) or the
presence of efﬂux pumps (21) are frequently encountered obstacles during drug
validation. Yet, the particularly lipophilic properties of CorA (18) and its in vivo efﬁcacy
against the ﬁlarial endobacterium Wolbachia (22) suggested that CorA was likely to
have an antimicrobial effect against other intracellular bacteria. We therefore con-
ducted the present study to investigate the effect of CorA on the human-pathogenic
Karp strain of O. tsutsugamushi both in vitro and in experimental mouse infections.
RESULTS
O. tsutsugamushi is highly susceptible in vitro to CorA. To investigate whether
CorA is able to inhibit growth in vitro of O. tsutsugamushi Karp, L929 cells seeded on
glass coverslips were infected with O. tsutsugamushi, washed, and grown in the
presence of 0.125 g/ml CorA, 10 g/ml tetracycline, or unsupplemented medium for
4 days. Fluorescence microscopy of 16S ﬂuorescence in situ hybridization (FISH)-
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phalloidin-costained cultures showed that CorA inhibited growth of O. tsutsugamushi to
a similar degree as the tetracycline control (Fig. 1A).
To determine the MIC of CorA for O. tsutsugamushi, traD copy numbers were
measured repeatedly by real-time PCR (23) from O. tsutsugamushi cell cultures, which
was performed in the presence of 2-fold serial dilutions of CorA. For O. tsutsugamushi,
an MIC of 0.0078 g/ml CorA was found (Fig. 1B, upper panel). We repeated a similar
experiment with R. typhi, which revealed an MIC of 0.125 g/ml (Fig. 1B, lower panel).
Thus, CorA was able to inhibit growth of O. tsutsugamushi at an MIC that was 16-fold
lower than that for R. typhi.
CorA protects against lethal O. tsutsugamushi infection in vivo. Next, we studied
whether CorA is effective in vivo against O. tsutsugamushi. BALB/c mice were infected
FIG 1 O. tsutsugamushi is susceptible to low doses of CorA in vitro. (A) 0.75  105 irradiated L929 cells
were grown on coverslips in 24-well plates, infected with O. tsutsugamushi Karp, and treated as indicated.
On day 4 p.i., cells treated with 10 g/ml tetracycline, 0.125 g/ml CorA, or medium were ﬁxed in 4%
paraformaldehyde (PFA). O. tsutsugamushi was labeled by FISH using the Atto590-labeled oligonucleo-
tide 16S probe Sitobion miscanthi L type symbiont (SMLS), followed by ﬁxation with 4% PFA. Actin ﬁbers
were stained with Alexa-488-conjugated phalloidin, followed by DAPI (4=,6-diamidino-2-phenylindole)
stain. Images were recorded by confocal microscopy (bar, 50 m). Arrows indicate O. tsutsugamushi
organisms. (B) 2  105 irradiated L929 cells were grown in 24-well plates, infected with O. tsutsugamushi
or R. typhi, and treated with 2-fold serial dilutions of CorA at the indicated concentrations, with 10 g/ml
tetracycline, or left untreated (in triplicates). Bacterial loads in infected cell cultures were measured by
traD qPCR (O. tsutsugamushi, upper panel) or ompB qPCR (R. typhi, lower panel) immediately p.i. and on
the indicated days p.i. The MIC is depicted in red. Shown are combined results from two independent
experiments (mean  standard deviation [SD]).
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intraperitoneally (i.p.) with the human-pathogenic Karp strain (23, 24). In order to
obtain the minimum dose required, BALB/c mice infected i.p. with 5,000 spot-forming
units (SFU) received CorA in decreasing doses (10-fold dilutions, from 100 g to 1 g),
100 g tetracycline, or phosphate-buffered saline (PBS) daily for 7 days. Treatment was
administered by i.p. injection and initiated at day 6 postinfection (p.i.), 1 day after the
onset of symptoms on day 5 p.i. as indicated by an increased clinical score (Fig. 2A). As
shown in Fig. 2A, 100 g/day of CorA protected 100% of treated mice from lethal
infection and body weight loss, while 10 g/day CorA only protected one-third of the
mice. Lower concentrations were ineffective, and all PBS-treated control mice suc-
cumbed to the infection by day 10 p.i. Thus, a daily dose of 100 g CorA, which in mice
with a starting weight of 18.31  1.09 g corresponds to 5.48  0.35 mg/kg (mean 
standard deviation [SD]), was sufﬁcient to protect from otherwise lethal infection.
In resource-poor settings, a short and effective therapy regimen is particularly
important. We therefore investigated whether treatment duration could be shortened
and treated the mice for 7, 6, 4, and 2 days. A 2-day course of CorA was sufﬁcient to
protect from lethal infection (Fig. 2B) and body weight loss and to induce clearance of
symptoms.
In order to test if CorA is able to protect when applied at an even more advanced
stage of infection, we delayed the initiation of treatment with CorA, tetracycline, or PBS
until day 7 p.i., i.e., after 2 symptomatic days, and continued the application for up to
7 days. In these experiments, 10/16 (60%) CorA- or tetracycline-treated mice survived
the infection, compared to 0/12 (0%) PBS-treated control mice (Fig. 2C). Thus, 100
g/day CorA rescued infected mice from lethal disease courses even at an advanced
infection stage.
FIG 2 CorA protects BALB/c mice from lethal intraperitoneal O. tsutsugamushi infection. BALB/c mice were infected i.p. with
O. tsutsugamushi Karp (5,000 SFU). (A) Mice were treated with a daily dose of 1 to 100 g CorA, 100 g tetracycline, or PBS
for up to 7 days, starting at day 6 p.i. Gray areas depict the treatment period. Shown are survival curves (upper panels), change
in body weight (middle panels), and combined clinical scores (lower panels; n  3 mice per group). (B) Mice were treated for
2 days with a daily dose of 100 g CorA or PBS, starting at day 6 p.i. (n  3 mice per group). (C) Infected mice were treated
for up to 7 days with a daily dose of 100 g CorA or PBS, starting at day 7 p.i. Shown are pooled data from two independent
experiments (n  14 to 16 mice per group). (A to C) Means  SD. Survival curves were analyzed by a log-rank (Mantle-Cox)
test comparing CorA-treated to PBS-treated groups. Body weight and score data were analyzed by 2-way ANOVA and
Bonferroni’s post hoc test. Shown are signiﬁcance levels when comparing the 100 g/day and 10 g/day groups on day 10
p.i. (A), or CorA- and PBS-treated groups on day 9 (B) or 10 (C) p.i. *, P  0.05; **, P  0.01; ***, P  0.001.
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The fulminant course of high-dose i.p. infection in BALB/c mice narrows the thera-
peutic window in this model to 1 to 2 days after the onset of symptoms. In order to
obtain a more protracted development of disease symptoms, we reduced the infection
dose to 1,000 SFU. Daily treatment with 100 g CorA, 100 g tetracycline, or PBS was
started on day 7 p.i. CorA protected all infected mice from lethal outcome, equivalent
to tetracycline, while 3/12 (25%) PBS-treated control mice survived the infection
(Fig. 3A, upper panels). In comparison to control mice, improvements of body weight
and clinical scores in CorA-treated mice could be observed after 2 days of treatment on
day 9 p.i. (Fig. 3A, middle and lower panels). To study whether CorA really reduces
bacterial replication in vivo, we quantiﬁed bacterial DNA in mouse organs in CorA-
treated and control mice on day 9 p.i., i.e., after 2 days of treatment. Bacterial DNA
concentrations in spleen and ascites, but not in blood, were signiﬁcantly lower from
mice that had received CorA compared to in PBS-treated controls (Fig. 3B).
O. tsutsugamushi remains susceptible to CorA after entering latency. It has been
shown that latent infection with O. tsutsugamushi is established in humans and mice
not only after immune-mediated clearance (25–27), but also after treatment with
antimicrobials (28). To test whether CorA prevents latency, we used cyclophosphamide
to immunosuppress mice that were intradermally (i.d.) infected with O. tsutsugamushi
(Fig. 4A) at days 54 and 57 p.i. and measured bacterial loads in spleens and lungs. O.
tsutsugamushi was reactivated, regardless of whether mice had been treated with CorA,
tetracycline, or PBS (Fig. 4B). Thus, treatment with CorA, similar to that with tetracycline,
FIG 3 CorA inhibits O. tsutsugamushi replication in vivo. BALB/c mice were infected i.p. with O. tsutsug-
amushi Karp (1,000 SFU) and treated daily for a course of 7 days with 100 g CorA, 100 g tetracycline,
or PBS i.p., starting at day 7 p.i. (A) The gray area depicts the treatment period for survival curves (upper
panel), body weight changes (middle panel), and clinical scores (lower panel). Shown are combined data
from two independent experiments (n  12 mice per group, means  SD). ***, P  0.001 by log-rank
(Mantle-Cox) test (survival curves) or by 2-way ANOVA with Bonferroni’s post hoc test (signiﬁcance level
refers to days 9 to 11 in weight charts and days 9 to 15 in score charts). (B) Mice infected with 1,000 SFU
O. tsutsugamushi i.p. and treated daily with 100 g CorA, 100 g tetracycline, or PBS i.p. for 2 days (day
7 and 8) were euthanized on day 9 p.i. Bacterial loads from DNA extracts of spleen, ascites, and blood
were measured by traD qPCR. Data are from one of two representative experiments (n  3 or 4 per
group). Mean  SD; *, P  0.05; ***, P  0.001 by one-way ANOVA and Bonferroni’s post hoc test.
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could not prevent latent infection with O. tsutsugamushi. To test whether latent O.
tsutsugamushi strains acquired antimicrobial resistance subsequent to antibiotic treat-
ment in vivo, we immunosuppressed i.p. infected, CorA- or tetracycline-treated mice
with cyclophosphamide on day 647 p.i. and reisolated O. tsutsugamushi on day 654 p.i.
in the presence of CorA, medium, or tetracycline (Fig. 4C). As shown in Fig. 4D, CorA was
able to suppress the growth of O. tsutsugamushi at concentrations up to its previously
determined MIC of 0.0078 g/ml (Fig. 1B), regardless of whether the mouse had been
treated with CorA or was CorA-naive (treated with tetracycline). To corroborate this
ﬁnding on the molecular level, we sequenced 4 regions within the rpoB and rpoC genes
(Fig. 4E) to which the CorA-binding determinant had been mapped (13), which showed
no differences from the wild type (data not shown), further demonstrating that a 7-day
treatment with CorA did not select for RNAP mutations. Thus, O. tsutsugamushi re-
mained fully susceptible to CorA posttreatment and after entering latency.
CorA-mediated protection against O. tsutsugamushi depends on adaptive im-
munity. We next investigated whether successful antimicrobial treatment against O.
tsutsugamushi could also be demonstrated in T- and B-cell-deﬁcient SCID mice. SCID
and BALB/c mice were infected i.p. with 5,000 SFU of O. tsutsugamushi Karp and treated
for 7 days with 100 g CorA, 100 g tetracycline, or PBS, starting at day 6 p.i. While
CorA-treated SCID mice were alive at the end of the treatment phase, all tetracycline-
FIG 4 O. tsutsugamushi enters latency despite CorA treatment but remains susceptible to CorA. (A) BALB/c mice were infected i.d. with
O. tsutsugamushi Karp (5,000 SFU) and treated for 7 days with a daily dose of 100 g CorA, 100 g tetracycline, or PBS, starting at day
13 p.i. On day 54 and 57 p.i., mice were immunosuppressed by cyclophosphamide (CP) i.p. or left untreated. Mice were euthanized on
day 61 p.i. (B) Bacterial loads in lung (left panel) and spleen (right panel) were quantiﬁed by traD qPCR. Shown are medians interquartile
range. (C) BALB/c mice were infected i.p. with O. tsutsugamushi Karp (5,000 SFU) and treated for 7 days with a daily dose of 100 g CorA
or 100 g tetracycline. After 647 days p.i., mice were immunosuppressed with cyclophosphamide and euthanized at 654 days p.i.
Reisolation of O. tsutsugamushi was performed from lung homogenates on irradiated L929 cells in the presence of the indicated
concentrations of antimicrobial. (D) Bacterial loads measured by traD qPCR in reisolation cultures from one CorA-treated (left) and one
tetracycline-treated mouse (right; mean  SD). No ATX, no antibiotics. (E) Genomic arrangement of rpoB and rpoC genes and primer
strategy. Primers are indicated below.
Kock et al. Antimicrobial Agents and Chemotherapy
April 2018 Volume 62 Issue 4 e01732-17 aac.asm.org 6
 o
n
 April 17, 2018 by BIO
ZENTRUM
 DER UNIV BASEL
http://aac.asm
.org/
D
ow
nloaded from
 
treated mice succumbed to the infection by day 10 p.i., before the treatment regimen
was completed. The CorA-treated SCID mice died on day 14 p.i. (Fig. 5A, upper panels).
Moreover, signiﬁcantly more weight loss and higher clinical scores, compared to the
BALB/c controls, were observed from day 13 p.i. in CorA-treated mice, compared to
days 8 and 9 p.i. in tetracycline-treated mice (Fig. 5A, middle and lower panels). In
contrast, CorA- or tetracycline-treated BALB/c mice fully recovered from the infection.
Also, while CorA inhibited bacterial replication in immunocompetent BALB/c mice (Fig.
3B), SCID mice had 100-fold higher bacteremia on day 13 p.i. compared to day 6 p.i.
(Fig. 5B), demonstrating that they were incapable of reducing bacterial replication
despite CorA treatment. Thus, survival of acute experimental O. tsutsugamushi infection
after antimicrobial treatment with CorA (as with tetracycline), as well as sustained
inhibition of bacterial replication in vivo, relies on the synergistic action of an adaptive
immune response.
DISCUSSION
The range of antimicrobial substances for treatment of scrub typhus is limited.
Several reports have demonstrated therapeutic failure of doxycycline, the gold stan-
dard of therapy in humans, further narrowing the spectrum of choices in certain
geographic areas (9, 29). Thus, there is an urgent need for novel compounds that are
FIG 5 Antimicrobial treatment of O. tsutsugamushi infection rescues BALB/c but not SCID mice. SCID mice
(n  4) or BALB/c mice (n  3) were infected i.p. with 5,000 SFU O. tsutsugamushi Karp and treated for
up to 7 days with a daily dose of 100 g CorA, 100 g tetracycline, or PBS, starting on day 6 p.i. (A) Shown
are survival curves (upper panels), body weight changes (mean  SD, middle panels), and clinical scores
(mean  SD, lower panels). Survival curves: *, P  0.05 by log-rank (Mantle-Cox) test; weight and score
charts: *, P  0.05; ***, P  0.001 by two-way ANOVA and Bonferroni’s post hoc test. (B) On days 6 and
13 p.i., O. tsutsugamushi bacteremia was measured by traD qPCR from blood of infected SCID mice that
had received 100 g/day CorA (median  interquartile range; **, P  0.01 by one-way ANOVA and
Bonferroni’s post hoc test).
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active against O. tsutsugamushi. Here, we present a thorough investigation of the
myxobacterial -pyrone compound CorA in its action against O. tsutsugamushi, and
introduce inhibition of the RNAP switch region as a potent new therapeutic drug target
for scrub typhus.
We showed that CorA was effective in vitro and in vivo against the human-
pathogenic O. tsutsugamushi strain Karp. The suppression of bacterial growth in the
presence of CorA was ﬁrst demonstrated by confocal microscopy using FISH in infected
L929 cells. FISH stains ribosomes, and the absence of a FISH stain indicates absence of
signiﬁcant bacterial metabolic activity. For accurate determination of the MIC, we used
the highly sensitive traD quantitative real-time PCR (qPCR) for quantiﬁcation of O.
tsutsugamushi DNA (23), similar to previously published qPCR-based protocols for
susceptibility testing of rickettsiae to antimicrobial agents (30, 31). The MIC of CorA was
0.0078 g/ml for O. tsutsugamushi. We also showed that CorA inhibited the growth of
R. typhi, but at a 16-fold higher MIC of 0.125 g/ml, which was comparable to the MIC
between 0.1 and 1 g/ml required for growth inhibition of Wolbachia spp. in insect
cells (22). Thus, this strikingly low MIC of CorA was speciﬁc for O. tsutsugamushi, and it
is lower than the MICs observed for any other antimicrobial substance that has been so
far tested against O. tsutsugamushi (32–36). A possible exception may be the tetracy-
cline derivative tigecycline, which was recently shown to inhibit growth in vitro of O.
tsutsugamushi (37), but which awaits susceptibility testing in vivo. However, the latter
drug is administered intravenously (i.v.) while oral (p.o.) formulations are to be ex-
pected for CorA.
At this stage, it remains unclear why O. tsutsugamushi is more susceptible than R.
typhi to CorA. By random mutagenesis of the RNAP subunits RpoB and RpoC in E. coli,
reduced susceptibility to CorA was related to speciﬁc amino acid substitutions in the
RNAP switch region (13, 14). Our in silico analysis of this binding region (see Fig. S1 in
the supplemental material) showed several amino acid variations between O. tsutsug-
amushi and R. typhi, and also variations in comparison to E. coli and S. aureus. Brieﬂy,
the RpoC D802E exchange is likely to improve CorA binding in O. tsutsugamushi, and
the RpoB E1279Q exchange in R. typhi may reduce CorA binding in R. typhi. In
combination, these exchanges could account for the differences in MIC between
O. tsutsugamushi and R. typhi (Fig. S1 and the supplemental material). However, the
different susceptibilities toward CorA could also be associated with different levels of
permeation of the drug, metabolic differences, or different growth rates of both
bacterial species. To investigate whether the RNAP sequence differences between both
species really contribute substantially to differences in MIC, MIC analyses with mutated
RNAPs will be required.
The human-pathogenic O. tsutsugamushi strain Karp produces lethal infections in i.p.
inoculated BALB/c mice (23, 26, 38), thus allowing for investigation of the ability of
potential therapeutics to protect from fatal outcomes. Titration of CorA in this highly
susceptible model showed that a daily dose of 100 g/mouse (corresponding to
5.48  0.35 mg/kg) for 7 days initiated at the onset of symptoms was sufﬁcient to
protect mice from lethal outcome. When delaying treatment until day 7 p.i., at an
advanced stage of infection indicated by a higher clinical score, CorA was able to
protect 60% of infected mice. With a sublethal infection dose, 100% of mice were
protected by CorA, and body weight loss and clinical scores were signiﬁcantly improved
compared to those of the PBS-treated survivors (Fig. 3A). Moreover, we demonstrated
that a short CorA treatment of 2 days protected all infected mice, suggesting that a very
short interruption of bacterial replication may be sufﬁcient for therapeutic success.
Possibly, a brief inhibition allows priming of adaptive immune mechanisms that
efﬁciently clear the infection. The fact that SCID mice, which lack both T and B cells,
were unable to control bacterial growth and therefore succumbed to the infection is
consistent with this interpretation. Notably, O. tsutsugamushi infections in humans have
been observed to respond to single-dose treatments with doxycycline (39), suggesting
that short-course treatment with CorA may be equally feasible in humans.
Although in vitro MICs of CorA are known for a wide range of pathogens (18),
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effective dose data from in vivo models are still scarce. In a previous study, CorA was
used at a concentration of 35 mg/kg for depletion of Wolbachia endobacteria in ﬁlarial
nematodes (22). We now show for O. tsutsugamushi that CorA is bioavailable and
bioactive in a mouse model system at an approximately 7-fold-lower dose. It was also
shown here that CorA reduced bacterial loads in ascites and spleen 2 days after
treatment, although bacteremia was not signiﬁcantly lowered. This ﬁnding parallels
reports in humans where PCR-positive blood samples, representing viable bacteria, are
found up to several weeks or even months post treatment with doxycycline or
azithromycin, despite clinical recovery (28, 40). Overall, CorA was highly effective at low
doses and after only two applications in protecting infected mice from lethal outcome
by reducing bacterial replication.
CorA was unable to prevent the establishment of latent O. tsutsugamushi infections.
Persistence of O. tsutsugamushi after antimicrobial treatment has been observed in all
commonly used classes of antimicrobials (28, 41). When we induced bacterial reacti-
vation by cyclophosphamide 647 days p.i., viable O. tsutsugamushi organisms from lung
homogenates could still be inhibited by CorA concentrations down to the previously
determined MIC of 0.0078 g/ml, suggesting that persistence was unrelated to the
selection of resistant mutants. As a limitation of our data, we cannot exclude the
possibility that resistant mutants were temporarily selected but lost before immuno-
suppression. However, the probability of such mutation events resulting in a tempo-
rarily selected and later lost resistance should be extremely low, and further, the loss of
such an acquired mutation would imply that the strains carrying it had a lower ﬁtness
compared to that of the nonmutated ones.
By demonstrating the effectiveness of CorA in vitro and in vivo, our study introduces
inhibition of the bacterial RNAP switch region with -pyrone antibiotics as a new and
highly potent therapeutic target for treatment of O. tsutsugamushi infections. The
rifamycins that also target RNAP, including rifampin, have long been known to be
active against O. tsutsugamushi and are favored in areas where poor doxycycline
responsiveness has been reported (10, 34, 41, 42). Given the crucial role of rifampin as
a ﬁrst-line bacteriostatic drug in tuberculosis treatment, it was recognized early that
rifampin is not an ideal standard regimen for treatment of scrub typhus. Tuberculosis
is a common infection in areas endemic for scrub typhus, and repeated scrub typhus
treatments might carry the risk of inducing rifampin resistance in latently tuberculosis-
infected patients (10). Since the binding site of CorA is remote from the rifamycin-
binding site (13), the use of an RNAP switch region inhibitor such as CorA for scrub
typhus would allow for speciﬁc therapy at very low dosage without applying selection
pressure in patients that are potentially coinfected with latent tuberculosis.
Altogether, we show here that O. tsutsugamushi was highly susceptible to CorA,
both in vitro and in experimental mouse infections. Similar to tetracycline, CorA
required adaptive immunity for antimicrobial action in vivo against O. tsutsugamushi.
CorA did not prevent the establishment of O. tsutsugamushi latency, but persistent
strains showed unaltered susceptibility to the compound and no mutations of RNAP
binding determinants. Our data suggest inhibition of the bacterial RNAP switch region
by CorA as a novel and highly potent bacterial target for antimicrobial therapy of scrub
typhus.
MATERIALS AND METHODS
Antimicrobial agents. The CorA producer strain Corallococcus coralloides B035 was cultivated in a
300-liter bioreactor with 2% Amberlite XAD-16 (DOW Chemicals, Germany) at the Leibniz Institute for
Natural Product Research and Infection Biology, Jena. CorA was recovered from the resulting extract by
elution with methanol and puriﬁed by two-step preparative reverse-phase fast performance liquid
chromatography (RP-FPLC) and high-performance liquid chromatography (HPLC) as described before
(16). The lyophilized compound was dissolved at a concentration of 10 mg/ml and stored at 80°C in
dimethyl sulfoxide before use. Tetracycline (Sigma, Deisenhofen, Germany) was dissolved in PBS at a
concentration of 10 mg/ml.
Rickettsia/Orientia cultures and MIC assays. O. tsutsugamushi Karp and R. typhi Wilmington were
kindly provided by J. Stenos (Australian Rickettsial Reference Laboratory, Geelong, Australia). Both strains
were grown in -irradiated murine L929 ﬁbroblasts (obtained from the German Collection of Microor-
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ganisms and Cell Cultures [DSMZ]) in RPMI medium (PAA, Linz, Austria) supplemented with 5% fetal calf
serum (FCS; Gibco/Invitrogen, Karlsruhe, Germany), 2% glutamine, and 2% HEPES buffer (both from PAA,
Linz, Austria) using 75-cm2 ﬂasks and subpassaged every 7 days (R. typhi) or 10 days (O. tsutsugamushi).
For susceptibility assays, -irradiated L929 cells were seeded at a concentration of 1  105 cells/well in
24-well plates (Greiner Bio-One, Frickenhausen, Germany). Infectious organisms were obtained from
continuous cultures after 4 days (R. typhi) or 10 days (O. tsutsugamushi) of culture. Brieﬂy, infected L929
cells were scraped from two 75-cm2 ﬂasks and disrupted by rocking with sterile glass beads. Bacteria
were puriﬁed by differential centrifugation as described previously (43). Infection was synchronized by
centrifugation at 133 g for 30 min, followed by a replacement of medium (see above) containing 2-fold
serial dilutions of CorA (0.0039 to 0.125 g/ml), 10 g/ml tetracycline, or unsupplemented medium. An
infectious dose was not calculated, but consistency in infectious doses was controlled for by quantiﬁ-
cation of bacterial loads of infected L929 cells immediately postinfection (p.i.; see following paragraph).
The lowest concentration of CorA preventing replication of rickettsiae to copy numbers higher than the
p.i. value was interpreted as the MIC.
PCR. To measure the bacterial load in susceptibility assays, samples from infected cell cultures were
taken immediately p.i. and after 2, 4, and 6 (O. tsutsugamushi) or 3 and 6 (R. typhi) days p.i. The cell culture
medium was removed, and the cell layer was treated with trypsin (200 l/well, 5 min at 37°C; PAA, Linz,
Austria), followed by thorough pipetting. Cell culture pellets were subjected to DNA extraction following
the QiaAmp DNA minikit protocol (Qiagen, Hilden, Germany). The O. tsutsugamushi load was quantiﬁed
by traD qPCR (23).
Rickettsiae were quantiﬁed using a previously described ompB-speciﬁc qPCR (44) adapted to the
SYBR green format. Brieﬂy, the PCR mix contained, in a total volume of 10 l, 400 nM each of primer
RickS2 (5=-TGTTAAGAATTTCTTTGCTCAAGGT-3=) and RickAS1 (5=-AGTAGCTAAGTCCTGCCATTG-3=; Tib-
molbiol, Berlin, Germany), a ﬁnal concentration of 2 mM MgCl2, 200 M deoxynucleoside triphosphates
(dNTPs), 100 g/ml bovine serum albumin (BSA), 0.1 of a 1:1,000 dilution of SYBR green I (Invitrogen,
Darmstadt, Germany), 0.25 U Hotstar Taq DNA polymerase (Qiagen), and 10 ng of template DNA. Enzyme
activation at 95°C for 15 min was followed by ampliﬁcation in 45 cycles of 15 s at 94°C, 15 s at 58°C, and
20 s at 72°C on a LightCycler 480 system (Roche, Mannheim, Germany). Speciﬁcity was conﬁrmed by
melting curve analysis (0.11°C/s, 5 acquisitions per °C). Results were expressed as traD copies/10 ng DNA
or transformed as y  log10(100  copies  1) and expressed as traD copies/g DNA.
To amplify the CorA binding determinant regions of the  (RpoB) and = (RpoC) subunits, the
following oligonucleotides were used. rpoB: rpoB_for, 5=-TCGACTCCAGTGTTTGATGGG-3= (nt 3610 to
3630); rpoB_rev2: 5=-CCATGAACGTATCTGCTCAGGA-3= (nt 87 to 108 [binds in rpoC]); rpoC region 1:
rpoC_Reg1_for, 5=-GATGCTAGATGCTGGGCGAT-3= (nt 774 to 793); rpoC_Reg1_rev, 5=-TACCACAACGCTC
AAGCTCA-3= (nt 1170 to 1189); rpoC region 2: rpoC_Reg2_for, 5=-TGCTGCTGGAGACCAAACTT-3= (nt 2118
to 2137); rpoC_Reg2_rev, 5=-GCCGCAACAATACCTACTGC-3= (nt 2749 to 2768); and rpoC region 3:
rpoC_Reg3_for, 5=-GCGTCGCTTAATACTGCATC-3= (nt 3519 to 3539); rpoC_Reg3_rev, 5=-CGGCTGGTACA
GGGTTTTA-3= (4079 to 4097). Products were visualized on precast 2.2% agarose gels (Lonza, Rockland,
ME) and bidirectionally sequenced by conventional Sanger sequencing (Seqlab, Göttingen, Germany).
Immunoﬂuorescence and FISH. L929 cells were seeded at a concentration of 0.75  105 cells/well
on 12-mm glass coverslips (Roth, Karlsruhe, Germany) placed in 24-well plates. Infection with O.
tsutsugamushi was performed as described above. After 4 days of culture, coverslips were ﬁxed in 4%
paraformaldehyde for 30 min at 4°C and stored in PBS. Cells were stained with Alexa-488-conjugated
phalloidin (Invitrogen, Darmstadt, Germany) at a dilution of 1:500 in 0.1% Triton X-100/2% FCS-PBS for
90 min at room temperature and ﬁxed with 4% paraformaldehyde for 30 min at 4°C. Fluorescence in situ
hybridization (FISH) for detection of Orientia ribosomal 16S rRNA was performed using the oligonucle-
otide probe Atto590-5=-TCHACGTCACCGTATYGC-3= (Biomers, Tübingen, Germany), a modiﬁcation of a
probe designed to recognize the close Orientia relative Sitobion miscanthi L type symbiont (SMLS) (45).
Samples were washed for 5 min in hybridization buffer (0.9 M NaCl, 0.02 M Tris-HCl, 0.01% SDS, and 30%
formamide) at 37°C. The probe (50 ng/l in hybridization buffer) was incubated at 46°C for 90 min in a
humid chamber, followed by washing for 15 min in washing buffer (0.102 M NaCl, 0.005 M EDTA, 0.02
M Tris-HCl, and 0.01% SDS) at 46°C. Samples were stained with DAPI (4=,6-diamidino-2-phenylindole;
0.005 mg/ml in 0.01% Triton X-100) for 5 min, washed in distilled water, mounted in ProLong Gold
medium (Invitrogen, Darmstadt, Germany) on glass slides, and viewed with an Olympus confocal
microscope. Images were analyzed with ImageJ 1.45s software (NIH, Bethesda, USA).
Experimental infections and treatment of mice. For in vivo infections, stock preparations of O.
tsutsugamushi Karp were prepared and quantiﬁed by measuring the concentration of spot-forming units
(SFU), as described previously (23). All animal experiments were carried out at the BSL3 facility of the
Bernhard Nocht Institute for Tropical Medicine (Hamburg, Germany). Female BALB/c mice (age 7 to 9
weeks, starting weight 16 to 20 g) were purchased from Charles River (Sulzfeld, Germany), kept in
individually ventilated cages, and infected i.p. with 1  103 to 5  103 SFU of O. tsutsugamushi Karp in
a volume of 0.5 ml PBS. Food and water were provided ad libitum.
For treatment purposes, CorA and tetracycline were diluted in PBS; mice received a volume of 0.2 ml
containing the indicated amount of compound via paramedian i.p. injection at the indicated frequencies.
During the acute disease phase, mice were weighed daily. The clinical score system described by
Gharaibeh et al. (43) was used to grade changes of fur (rufﬂing) and general condition (tiredness,
distended abdomen, etc.; for details, see Table S1 in the supplemental material). Mice were sacriﬁced by
cervical dislocation during ketamine-xylazine anesthesia. Organ samples were processed as described
previously (23).
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Software and statistics. GraphPad Prism version 5.0 for Mac OS X (GraphPad Software, La Jolla, CA)
was used for data analysis. Hypotheses were tested by one-way or two-way analysis of variance (ANOVA)
with Bonferroni’s post hoc correction. Survival curves were analyzed by a log-rank (Mantle-Cox) test.
A P value of 0.05 was considered signiﬁcant. For sequence analysis and ClustalW multiple alignments,
MEGA6.06 and BioEdit 7.0.5.3 were used.
Ethics statement. The Animal Protection Commission and the Health Department of the State of
Hamburg, Germany approved the animal protocol (approval number 67/12). The protocol adheres to the
national regulations (German Animal Welfare Act).
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